Suven Life Sciences Limited (SUVEN) AI Stock Analysis

• Market Cap: ₹33.40B
• Dividend Yield: N/A
• Average Volume (3M): 14.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -4.48
• Shares Outstanding: 231,951,810
• 10 Day Avg. Volume: 16,308
• 30 Day Avg. Volume: 14,834
• PEG Ratio: -0.31
• Price to Book (P/B): 24.25
• Price to Sales (P/S): 400.69
• P/FCF Ratio: -14.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ₹131.00 ▼(-20.61% Downside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is driven primarily by very weak financial performance—sharp profitability deterioration, negative gross profit, and persistent operating/free-cash-flow burn—partly offset by minimal leverage. Technicals add pressure with the stock trading below key moving averages and negative MACD, while valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield is available.

Positive Factors

Very low financial leverage

Near-zero debt materially reduces solvency and interest-service risk, giving the company time to execute a turnaround without imminent covenant pressure. Low leverage preserves optionality for strategic investments or external financing on better terms if operations stabilize.

Contract R&D fee-based business model

A fee-based contract research model offers recurring, project-driven revenue streams tied to clients' discovery pipelines. Over time this creates durable demand from pharma/biotech outsourcing trends, enabling predictable backlog and milestone billing when client relationships and capabilities are maintained.

Specialized medicinal chemistry capabilities

Specialized expertise in medicinal chemistry is a high-barrier service valued by drug developers; this skill set supports differentiation, higher billing rates, and stickier client engagements. Such technical capability underpins long-term competitive positioning in discovery outsourcing.

Negative Factors

Declining revenue and margins

Sustained revenue decline and sharply negative margins indicate weakening demand or pricing pressure and reduced operating leverage. Over months this erodes capacity to rebuild capabilities, undermines margin recovery prospects, and makes funding core R&D or client-development initiatives more difficult.

Negative gross profit and persistent cash burn

Negative gross profit and recurring operating cash outflows show the business is not self-funding. Persistent cash burn increases probability of external financing, dilution, or enforced cost cuts, limiting long-term investment in staff, infrastructure, and client programs necessary to regain growth.

Eroding equity and negative ROE

Sharp equity erosion and deeply negative ROE signal capital depletion from sustained losses, reducing the cushion against future shocks. A weaker capital base constrains strategic flexibility, raises financing costs, and heightens execution risk for turnaround plans over the coming months.

Suven Life Sciences Limited Business Overview & Revenue Model

Company Description

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

How the Company Makes Money

Suven Life Sciences primarily makes money by providing contract research and development services to external customers, typically pharmaceutical and biotechnology companies. Revenue is generated through fee-based work for drug discovery and development support (e.g., project-based or milestone-based engagements for research activities such as medicinal chemistry and associated discovery services). The company may also earn income from licensing or commercialization of intellectual property arising from its research programs; however, specific details (e.g., the mix of service revenue versus licensing/royalty income, named partners, or the contribution of any single agreement) are null due to unavailable specific data in this context.

Suven Life Sciences Limited Financial Statement Overview

Summary

Financial performance is very weak: revenue declined in FY2025 (-12.1%) and profitability deteriorated sharply with a deeply negative net margin (-24.2%) and negative gross profit, while operating losses persist. Cash flow is a major risk with consistently negative operating and free cash flow, indicating ongoing cash burn. The main offset is very low debt, but equity erosion from sustained losses weakens the capital base.

Income Statement

Operating performance is very weak and deteriorating. Revenue fell in FY2025 (-12.1%) after being roughly flat-to-down in prior years, and profitability is deeply negative: FY2025 shows a sharply worse net margin (-24.2%) versus FY2024 (-9.0%). Gross profit also turned negative in FY2025, indicating severe cost pressure or adverse mix, while operating losses (EBIT/EBITDA) remain substantial across the period—leaving limited evidence of an earnings recovery trajectory.

Balance Sheet

Leverage is a key strength: debt is essentially zero in FY2025 (and very low in prior years), which reduces solvency risk. However, the balance sheet has weakened materially as equity declined sharply from FY2024 to FY2025, reflecting sustained losses; returns on equity are deeply negative in FY2025, signaling value erosion. Overall, the company has low financial leverage but shrinking capital buffers.

Cash Flow

Cash generation is consistently negative. Operating cash flow is deeply negative every year provided (including FY2025), and free cash flow is also substantially negative, indicating the business is not self-funding. While free cash flow is not worse than net income in several years (i.e., losses are accompanied by similarly negative cash flow), the persistent cash burn raises funding and sustainability risk unless operations improve or external support is available.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	75.17M	66.56M	116.93M	135.39M	118.44M	134.78M
Gross Profit	-17.93M	-276.33M	108.69M	129.74M	-137.31M	133.75M
EBITDA	-1.78B	-1.55B	-992.78M	-1.11B	-1.17B	-721.87M
Net Income	-1.84B	-1.61B	-1.05B	-1.18B	-1.22B	-721.51M
Balance Sheet
Total Assets	0.00	1.35B	2.85B	3.89B	1.08B	1.28B
Cash, Cash Equivalents and Short-Term Investments	600.05M	600.05M	2.40B	2.31B	504.36M	463.54M
Total Debt	0.00	0.00	7.10M	16.05M	32.09M	47.64M
Total Liabilities	-1.10B	251.97M	148.62M	135.91M	118.89M	204.12M
Stockholders Equity	1.10B	1.10B	2.70B	3.75B	961.45M	1.08B
Cash Flow
Free Cash Flow	0.00	-1.86B	-1.15B	-1.06B	-1.47B	-1.02B
Operating Cash Flow	0.00	-1.48B	-1.15B	-1.03B	-1.28B	-960.24M
Investing Cash Flow	0.00	1.49B	944.36M	-2.61B	-222.29M	558.40M
Financing Cash Flow	0.00	-7.10M	-10.54M	3.96B	1.46B	348.56M

Suven Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	68 Neutral	₹48.67B	30.45	―	0.13%	14.35%	15.79%
AARTIDRUGS	57 Neutral	₹32.27B	23.17	―	0.24%	4.08%	31.52%
GUFICBIO	57 Neutral	₹29.12B	67.80	―	0.03%	7.78%	-34.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPARC	44 Neutral	₹40.31B	-13.56	―	―	-0.82%	34.67%
SUVEN	43 Neutral	₹33.40B	-9.14	―	―	―	―

Suven Life Sciences Limited Corporate Events

Suven Life Sciences Opens Special Window for Re-Lodgment of Physical Share Transfers

Suven Life Sciences has notified stock exchanges that it has published newspaper advertisements announcing a special window for re-lodgment of transfer requests for physical securities. The notice, released in Business Standard and Nava Telangana on February 19, 2026, is part of the company’s compliance with SEBI listing regulations and is also being made available on its website for shareholder reference.

The initiative aims to inform shareholders holding physical share certificates about the process and timeframe for re-lodging transfer requests under the regulatory framework. By proactively publicizing this special window and providing centralized information access online, Suven is seeking to facilitate smoother share transfer compliance, reduce investor grievances, and align its securities handling practices with evolving market and regulatory expectations.

Suven Life Sciences Attributes Share Price Surge to Market Speculation

Suven Life Sciences Limited has responded to a query from the National Stock Exchange of India regarding a significant recent movement in its share price and trading volumes. The company stated that it has already been disclosing all material events in compliance with SEBI’s disclosure rules and confirmed that, at present, there is no undisclosed material information or pending announcement that could explain the recent price or volume changes. Management attributed the movement in its stock to market speculation and requested that this clarification be shared with the public and posted on both the exchange’s and the company’s websites to reassure investors about the transparency of its disclosures.